Generic Medicine Info
May be taken with or without food.
Acute pulmonary insufficiency, respiratory depression, sleep apnoea, acute narrow-angle glaucoma, obsessional state, myasthenia gravis. Severe hepatic impairment. Pregnancy (planning a pregnancy, 1st or 3rd trimester).
Special Precautions
Patients with respiratory disease (e.g. COPD), history of alcoholism or drug abuse, psychiatric or personality disorders; at risk of falls. Debilitated patients. Renal and mild to moderate hepatic impairment. Children and elderly. Pregnancy (2nd trimester) and lactation. Not indicated for primary treatment of psychotic illness or depressive disorders. Avoid abrupt withdrawal. Patient Counselling This drug may cause sedation, amnesia, impaired concentration, dizziness, impaired muscular function or blurred vision, if affected, do not drive or operate machinery. Monitoring Parameters Monitor respiratory and cardiovascular status, blood pressure, heart rate, symptoms of anxiety; CBC, LFT, LDH (prolonged use).
Adverse Reactions
Significant: Physical and psychological dependence, withdrawal symptoms, anterograde amnesia, paradoxical reactions (including hyperactive or aggressive behaviour). Blood and lymphatic system disorders: Blood dyscrasia (e.g. agranulocytosis, leucopenia, thrombocytopenia, pancytopenia). General disorders and administration site conditions: Asthenia, fatigue, ataxia. Injury, poisoning and procedural complications: Injection site pain (IV/IM). Investigations: Elevated liver enzymes. Musculoskeletal and connective tissue disorders: Muscle weakness. Nervous system disorders: Drowsiness, sedation, dizziness, unsteadiness. Psychiatric disorders: Confusion, depression, hallucinations, stupor. Respiratory, thoracic and mediastinal disorders: Respiratory failure, apnoea. Skin and subcutaneous tissue disorders: Rash. Vascular disorders: Hypotension.
Potentially Fatal: Respiratory depression, anaphylactoid reactions (e.g. angioedema in the tongue, glottis or larynx).
Drug Interactions
May enhance CNS depressant effect of NA oxybate, neuroleptics, antipsychotics, tranquilisers, antidepressants, hypnotics, anaesthetics, barbiturates (e.g. phenobarbital), sedative antihistamines. Enhanced sedative effect with HIV-protease inhibitors, cisapride, lofexidine, nabilone, disulfiram, and muscle relaxants (e.g. tizanidine, baclofen). Increased serum concentration with anti-epileptic agents (e.g. valproate). Reduced clearance and enhanced actions with CYP450 inhibitors (e.g. cimetidine, isoniazid, erythromycin, omeprazole). Increased clearance and reduced effects with CYP450 inducers (e.g. rifampicin). Antagonistic effect with dopaminergics (e.g. levodopa). Reduced effects with theophylline or aminophylline. Scopolamine increases risk of sedation, hallucination and irrational behaviour. Antacids may delay absorption of lorazepam. Enhanced hypotensive effect with ACE inhibitors, angiotensin II receptor blockers, Ca channel blockers, diuretics, β-blockers.
CIMS Class
Anticonvulsants / Antivertigo Drugs / Anxiolytics
ATC Classification
N05BA06 - lorazepam ; Belongs to the class of benzodiazepine derivatives anxiolytics. Used in the management of anxiety, agitation or tension.
Disclaimer: This information is independently developed by CIMS based on lorazepam from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in